Madrigal Pharmaceuticals (MDGL) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving Madrigal Pharmaceuticals (MDGL) right now is Rezdiffra revenue ramp: Rezdiffra net sales grew about 127% year over year to roughly $311 million in the first quarter of 2026, crossing $1.1 billion on a trailing-twelve-month basis less than two years after launch. Revenue (TTM) is ~$1.1B. If that keeps playing out, the setup is favourable; the risk to it is mDGL is a single-product company, so the entire thesis hinges on Rezdiffra, and any slowdown in patient adds, reimbursement pressure or safety signal would hit hard. No one can predict where MDGL trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Madrigal Pharmaceuticals (MDGL) higher?
1. Rezdiffra revenue ramp
Rezdiffra net sales grew about 127% year over year to roughly $311 million in the first quarter of 2026, crossing $1.1 billion on a trailing-twelve-month basis less than two years after launch. Patient count reached more than 42,250, up about 2.5x from a year earlier. The central driver is whether that adoption curve keeps compounding as more prescribers and diagnosed patients enter the funnel.
2. MASH market expansion
The diagnosed F2/F3 MASH population seen by target liver specialists in the US grew nearly 50% from about 315,000 to 460,000 patients between year-end 2023 and year-end 2025. A larger diagnosed pool and rising disease awareness expand the addressable market Rezdiffra can penetrate as the first approved therapy.
3. Label and pipeline expansion
Madrigal is pursuing broader use of resmetirom, including in earlier and more advanced (compensated cirrhosis) MASH populations, and has added assets through business development, including an RNAi MASH deal sourced from China. Success in widening the label and building a multi-asset pipeline would reduce reliance on a single indication.
4. Path toward profitability
The company reported a net loss of about $94 million in the first quarter of 2026 against roughly $404 million of operating expenses, ending the period with about $818 million in cash and marketable securities. The bull case rests on revenue scaling past a heavy commercial and R&D cost base to reach sustained profitability.
What could weigh on MDGL?
MDGL is a single-product company, so the entire thesis hinges on Rezdiffra, and any slowdown in patient adds, reimbursement pressure or safety signal would hit hard. Competition is intensifying: Novo Nordisk's Wegovy won FDA approval in MASH in 2025, and late-stage rivals include Viking Therapeutics' VK2809 and FGF21 analogs such as Akero's efruxifermin, 89Bio's pegozafermin and GSK's efimosfermin. The company remains unprofitable and could need additional capital or carry debt (it has an outstanding term loan) if losses persist. Valuation is rich relative to current sales, leaving little room for execution stumbles. Biotech-specific risks around clinical trials, regulatory decisions and manufacturing also apply.
Where MDGL trades today
A forecast starts from where the stock actually is. These are MDGL's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for MDGL as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a MDGL forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the MDGL guide and whether MDGL is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the MDGL outlook
The bottom line: what is driving Madrigal Pharmaceuticals (MDGL) is Rezdiffra revenue ramp, with revenue (ttm) at ~$1.1B. If that keeps playing out the setup is favourable; the risk is mDGL is a single-product company, so the entire thesis hinges on Rezdiffra, and any slowdown in patient adds, reimbursement pressure or safety signal would hit hard. No one can predict the price, so treat any MDGL forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
More on MDGL
- MDGL stock guide (what the company does, ETFs that hold it, similar stocks, and the themes it fits)
- Is MDGL a buy? (the case for, the risks, and a framework to decide)
- Does MDGL pay a dividend?
Build a basket around MDGL with Walnut
Use Madrigal Pharmaceuticals as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Madrigal Pharmaceuticals (MDGL)?
+
No one can reliably predict where MDGL will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Madrigal Pharmaceuticals higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive MDGL higher?
+
The main growth drivers are Rezdiffra revenue ramp; MASH market expansion; Label and pipeline expansion. Whether they play out is the real question, not a guaranteed path.
What are the risks to MDGL?
+
MDGL is a single-product company, so the entire thesis hinges on Rezdiffra, and any slowdown in patient adds, reimbursement pressure or safety signal would hit hard. Competition is intensifying: Novo Nordisk's Wegovy won FDA approval in MASH in 2025, and late-stage rivals include Viking Therapeutics' VK2809 and FGF21 analogs such as Akero's efruxifermin, 89Bio's pegozafermin and GSK's efimosfermin. The company remains unprofitable and could need additional capital or carry debt (it has an outstanding term loan) if losses persist. Valuation is rich relative to current sales, leaving little room for execution stumbles. Biotech-specific risks around clinical trials, regulatory decisions and manufacturing also apply.
Will MDGL stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Madrigal Pharmaceuticals's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is MDGL a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the MDGL "is it a buy?" page for a framework. Walnut is not an investment adviser.
How fast is Rezdiffra growing?
+
Rezdiffra net sales grew about 127% year over year to roughly $311 million in the first quarter of 2026, and trailing-twelve-month sales have surpassed $1.1 billion. More than 42,250 patients were on the therapy as of the end of the quarter.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.